Biomarker Discovery: 6 Decisions That Can Improve Drug Development and Precision Medicine Investments

The global biomarker discovery market was valued at USD 22.47 billion in 2025 and is projected to reach approximately USD 67.91 billion by 2035, growing at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2035.

As pharmaceutical and biotechnology companies invest in precision medicine, targeted therapies, and advanced diagnostics, biomarkers are becoming increasingly important in identifying disease mechanisms, selecting patients for clinical trials, and evaluating treatment responses. Advances in genomics, proteomics, liquid biopsy, and artificial intelligence are also expanding the range of biological signals researchers can investigate.

However, identifying a promising biomarker does not guarantee clinical or commercial success. Companies must establish that the biomarker is reproducible, clinically meaningful, and suitable for its intended application.

For research and development teams, the key question is how to identify biomarkers that can generate reliable evidence, support better development decisions, and ultimately translate into clinical applications.

1. Which Biomarkers Should Research Teams Prioritize?

Biomarkers can provide information about disease presence, biological processes, treatment response, and potential safety risks. The challenge is determining which candidates are most relevant to a particular research objective.

Protein biomarkers can reveal changes in biological pathways, while genetic biomarkers can help identify mutations and molecular characteristics associated with disease. Metabolic, cellular, and epigenetic biomarkers offer additional perspectives on disease progression and biological response.

Before beginning a discovery program, research teams should assess:

• Clinical relevance: Is the biomarker linked to a meaningful disease process or treatment outcome?
• Research objective: Is it intended for diagnosis, patient selection, treatment monitoring, or drug development?
• Sample availability: Can suitable blood, tissue, or other biological samples be obtained consistently?
• Analytical feasibility: Can the biomarker be measured accurately with available technologies?
• Validation potential: Can the finding be tested in an independent patient population?

A clearly defined research objective helps prevent teams from spending resources on molecular signals that are statistically interesting but have limited clinical relevance.

2. How Can Biomarkers Improve Drug Discovery and Clinical Trials?

Biomarkers can support several stages of pharmaceutical development, from identifying potential drug targets to monitoring treatment effects. They can also help researchers identify patient groups more likely to respond to a therapy, making clinical-trial design more focused.

The growing importance of this approach is reflected in oncology research. According to the linked market analysis, an assessment of 47,271 solid tumors found that the proportion carrying standard-of-care predictive biomarkers increased from 8.9% in 2017 to 31.6% in 2022.

For drug developers, biomarker-guided research can help answer important questions:

• Which patients are most likely to benefit from a candidate treatment?
• Can researchers identify early indicators of treatment response?
• Could a biomarker help distinguish treatment-related effects from disease progression?
• Can patient stratification improve the relevance of clinical-trial results?
• Which biological measurements should be included in the development program?

These applications can improve research efficiency, but biomarker-based patient selection must be supported by appropriate evidence. A marker associated with a disease does not necessarily predict whether a patient will respond to a specific treatment.

3. Should Companies Invest in Genomics, Proteomics, or Multi-Omics?

Different technologies reveal different aspects of biology, so the appropriate platform depends on the research question.

• Genomics: Identifies genetic variants, mutations, and molecular changes that may be associated with disease or treatment response.
• Proteomics: Examines proteins and their abundance or modifications, providing insights into biological activity and disease pathways.
• Metabolomics: Measures small molecules involved in metabolic processes and can help reveal changes associated with disease or treatment.
• Transcriptomics: Studies RNA expression to understand how genes are activated or regulated.
• Multi-omics: Combines information from multiple biological layers to investigate complex relationships that may not be apparent through a single technology.

Genomics accounted for 35.3% of the technology segment in 2025, while proteomics is identified as the fastest-growing technology segment.

This distinction matters for investment planning. Genomics may be appropriate when genetic variation is central to the research objective, while proteomics can provide more direct evidence of changes in protein activity. Multi-omics may offer broader biological insight but also introduces greater data-integration, analytical, and interpretation requirements.

Rather than selecting a platform because it is widely adopted, companies should evaluate its ability to answer the specific biological question and produce results that can be independently validated.

4. Can AI and Liquid Biopsy Accelerate Biomarker Discovery?

Artificial intelligence and machine learning are helping researchers analyze complex datasets containing genomic, proteomic, clinical, imaging, and other biological information. These methods can identify patterns, explore combinations of potential biomarkers, and generate hypotheses for further investigation.

Liquid biopsy is also expanding discovery opportunities by enabling researchers to examine circulating tumor DNA, RNA, proteins, and other biological signals in blood or other bodily fluids. In oncology, these approaches can support research into early disease detection, residual disease, and treatment-response monitoring.

However, advanced technologies do not eliminate the need for rigorous scientific validation.

Research teams should consider:

• Data quality: Are the datasets sufficiently complete and consistent?
• Population diversity: Do the samples represent the intended patient population?
• Model reliability: Have AI-generated findings been tested on independent datasets?
• Analytical performance: Can the biomarker be measured reliably across laboratories or platforms?
• Clinical utility: Does the finding provide information that can influence a meaningful decision?

AI can help narrow the field of potential biomarkers, while liquid biopsy can enable less invasive sample collection in suitable applications. Their value ultimately depends on whether the findings are reproducible and clinically useful.

5. How Can Companies Reduce Biomarker Validation Risks?

One of the major challenges in biomarker discovery is translating an initial research finding into a dependable clinical or drug-development tool.

A biomarker may appear promising in a small study but perform less consistently in a larger or more diverse population. Differences in sample handling, analytical methods, patient characteristics, and statistical approaches can all affect reproducibility.

The linked market analysis highlights the difficulty of clinical translation, noting that only a small proportion of published biomarkers ultimately achieve routine clinical adoption.

Companies can reduce these risks by establishing a structured validation process:

1. Define the intended use. Specify whether the biomarker will support research, diagnosis, prognosis, treatment selection, or monitoring.
2. Standardize sample handling. Establish consistent collection, storage, preparation, and processing procedures.
3. Verify analytical performance. Evaluate accuracy, precision, sensitivity, specificity, and reproducibility as appropriate.
4. Use independent validation cohorts. Test whether the findings hold beyond the original discovery dataset.
5. Assess clinical relevance. Determine whether the biomarker provides useful information beyond existing methods.
6. Plan regulatory requirements early. Consider the evidence needed for the intended diagnostic or clinical application.

This approach can help teams identify weaknesses before committing to expensive clinical studies or commercialization efforts.

6. Should Companies Build Internal Capabilities or Outsource Biomarker Research?

Biomarker discovery often requires specialized instruments, laboratory infrastructure, bioinformatics expertise, and access to appropriate biological samples. Developing all these capabilities internally can be expensive, particularly for smaller biotechnology companies or programs that require multiple advanced technologies.

External research partners and contract research organizations (CROs) can provide access to sequencing, proteomics, mass spectrometry, bioinformatics, sample management, and validation services.

According to the market analysis, pharmaceutical and biotechnology companies accounted for 42.8% of the end-user segment in 2025, while CROs are identified as the fastest-growing end-user segment.

The decision to outsource should depend on the complexity, duration, and strategic importance of the research program.

• Internal capabilities may be appropriate when biomarker research is continuous, strategically sensitive, or closely integrated with proprietary drug-development programs.
• External partners may be useful when specialized expertise, advanced platforms, or additional research capacity are required.
• Hybrid models can combine internal scientific leadership with external analytical or validation capabilities.

Before selecting a partner, companies should assess technical expertise, data ownership, sample governance, quality systems, turnaround times, and the ability to reproduce results. Outsourcing can provide flexibility, but clear protocols and oversight remain essential.

What Do Market Trends Mean for Future Biomarker Investments?

Several developments are shaping demand across the biomarker discovery market:

• Consumables: Accounted for 55.5% of the product segment in 2025, supported by recurring demand for reagents, assay kits, and sample-preparation materials.
• Protein biomarkers: Held 34.6% of the biomarker-type segment, reflecting their use in disease research, therapeutic development, and clinical studies.
• Drug discovery and development: Represented 38.7% of applications, highlighting the role of biomarkers in target identification, patient stratification, and treatment-response assessment.
• Companion diagnostics: Are expected to expand rapidly as targeted therapies increasingly depend on tests that identify patients likely to benefit from specific treatments.
• Software and analytics: Are gaining importance as researchers integrate AI, bioinformatics, and multi-omics datasets.
• North America: Accounted for 42.5% of global market revenue in 2025, supported by pharmaceutical R&D, precision-medicine infrastructure, and established research capabilities.

These trends indicate opportunities across laboratory consumables, analytical platforms, research services, and biomarker-based development programs. However, market growth alone does not determine the best investment. Companies should evaluate the scientific problem, the availability of suitable samples, the cost of validation, and the commercial or clinical value of the intended application.

Conclusion

Biomarker discovery is becoming increasingly important to precision medicine, targeted drug development, and advanced diagnostics. Genomics, proteomics, liquid biopsy, and AI are creating new ways to identify biological signals and understand disease, but their commercial value depends on reliable measurement and clinical relevance.

Research teams should prioritize clearly defined objectives, select technologies that fit their scientific questions, validate findings in independent populations, and establish regulatory and partnership requirements early.

The most valuable biomarker is not simply one that can be discovered. It is one that can be measured reliably, validated convincingly, and used to improve a meaningful research or clinical decision.

Explore the Full Market Report: https://www.cervicornconsulting.com/sample/3035